Hatem Azim has been appointed chief medical officer at Germany-based Emergence Therapeutics AG, a developer of antibody-drug conjugates. He joins from Laboratoires Pierre Fabre where he was head of oncology, early clinical development. Prior to this, he was head of clinical development at Innate Pharma SA. Dr Azim holds a medical degree from Cairo University in Egypt, a master’s degree in oncology from Newcastle University, UK, and a PhD from the Université Libre de Bruxelles in Belgium.
Emergence Therapeutics announced the appointment on 7 June 2022.
Copyright 2022 Evernow Publishing Ltd